Skip to main content
SpringerLink
Log in

Potassium Channel Openers in Myocardial Ischaemia

Therapeutic Potential of Nicorandil

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Potassium channel openers or agonists represent a novel new class of compounds in the treatment of a range of cardiovascular disorders, particularly angina pectoris and hypertension. Nicorandil is the only clinically available potassium channel opener with antianginal effects, and with comparable efficacy and tolerability to existing antianginal therapy. It confers benefits through a dual action: opening the mitochondrial Katp channels leading to preconditioning of the myocardium and a nitrate-like effect. Myocardial preconditioning is important in reducing infarct size, severity of stunning and cardiac arrhythmias. These effects make nicorandil a unique antianginal compound that reduces both pre- and after-load and improves coronary blood flow. Comparative and noncomparative studies support the use of nicorandil as monotherapy or in combination with other antianginal therapy for stable angina pectoris. However, large studies are required to confirm its role in the treatment of acute coronary syndromes despite the favourable results from small studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983; 305: 147–8

    Article  PubMed  CAS  Google Scholar 

  2. Shyng S, Nichols C. Octameric stoichiometry of the KATP channel complex. J Gen Physiol 1997; 110: 655–64

    Article  PubMed  CAS  Google Scholar 

  3. Gerald KD, Paucek P, Yarov-Yarooy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP -sensitive K+ channels: possible mechanism of cardioprotection. Circ Res 1997; 81: 1072–82

    Article  Google Scholar 

  4. Liu Y, Sato T, O’Rourke B, et al. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97: 2463–9

    Article  PubMed  CAS  Google Scholar 

  5. Sato T, Sasaki N, Seharaseyon J, et al. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K ATPChannels in ischaemic cardioprotection. Circulation 2000; 101: 2418–23

    Article  PubMed  CAS  Google Scholar 

  6. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischaemia a delay of cell injury in ischaemic myocardium. Circulation 1986; 74: 1124–36

    Article  PubMed  CAS  Google Scholar 

  7. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87: 893–9

    Article  PubMed  CAS  Google Scholar 

  8. Gysembergh A, Margonari H, Loufoua J, et al. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart. Am J Physiol 1998; 274: H955–H64

    PubMed  CAS  Google Scholar 

  9. Koning MM, Gho BC, van Klaarwater E, et al. Rapid ventricular pacing produces myocardial protection by nonischemic activation of K+ atpchannels. Circulation 1996; 93: 178–86

    Article  PubMed  CAS  Google Scholar 

  10. Hoag JB, Qian YZ, Nayeem MA, et al. ATP-sensitive potassium channel mediates delayed ischemic protection by heat stress in rabbit heart. Am J Physiol 1997; 273: H2458–H64

    PubMed  CAS  Google Scholar 

  11. Gho BC, Schoemaker RG, van den Doel MA, et al. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996; 94: 2193–200

    Article  PubMed  CAS  Google Scholar 

  12. Dunker DJ and Verdouw PD. Role of Katp channels in Ischaemic Preconditioning and Cardioprotection. Cardiovas Drugs Ther 2000; 14: 7–16

    Article  Google Scholar 

  13. Tomai F, Crea F, Gaspardone A, et al. Ischaemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700–5

    Article  PubMed  CAS  Google Scholar 

  14. Marber MS, Joy MD, Yellon DM. Warm-up in angina: is it ischaemic preconditioning? Br Heart J 1994; 72: 213–5

    Article  PubMed  CAS  Google Scholar 

  15. Behar S, Reicher-Reiss H, Abinader E, et al. The prognostic significance of angina pectoris preceding the occurrence of a first acute myocardial infarction in 4166 consecutive hospitalized patients. Am Heart J 1992; 123: 1481–6

    Article  PubMed  CAS  Google Scholar 

  16. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size: a role for ischaemic preconditioning. Circulation 1995; 91: 291–7

    Article  PubMed  CAS  Google Scholar 

  17. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1-adenosine receptors in rabbit heart. Circulation 1991; 84: 350–6

    Article  PubMed  CAS  Google Scholar 

  18. Thornton J, Liu GS, Olsson RA, et al. Intravenous pre-treatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85: 659–65

    Article  PubMed  CAS  Google Scholar 

  19. Goto M, Liu Y, Xi-Ming Y, et al. Role os bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995; 77: 611–21

    Article  PubMed  CAS  Google Scholar 

  20. Kariya T, Minatoguchi S, Ohno T, et al. Infarct size-reducing effect of ischemic preconditioning is related to alpha/1b-adrenoceptors but not alpha/1a-adrenoceptors in rabbits. J Cardiovasc Pharmacol 1997; 30: 437–45

    Article  PubMed  CAS  Google Scholar 

  21. Tanaka M, Fujiwara H, Yamasaki K, et al. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. Cardiovasc Res 1994; 28: 980–6

    Article  PubMed  CAS  Google Scholar 

  22. Ytreus K, Liu Y, Downey J. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physio 1994; 266: HI 145–52

    Google Scholar 

  23. Gross GJ, Auchampach J. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in the dogs. Circ Res 1992; 70: 223–33

    Article  PubMed  CAS  Google Scholar 

  24. Light PE, Sabir AA, Allen BG, et al. Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels, a possible mechanistic link to ischemic preconditioning. Circ Res 1996; 79: 399–406

    Article  PubMed  CAS  Google Scholar 

  25. Parratt JR, Kane KA. KATPChannels in ischaemic preconditioning. Cardiovasc Res 1994; 28: 783–7

    Article  PubMed  CAS  Google Scholar 

  26. Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs 1989; 37: 523–50

    Article  PubMed  CAS  Google Scholar 

  27. Kukovetz WR, Holzmann S, Braida C. Dual mechanism of relaxing effect of nicorandil by stimulation of cyclic GMP formation and hyperpolarization. J Cardiovasc Pharmacol 1991; 17: 627–33

    Article  PubMed  CAS  Google Scholar 

  28. Kukovetz WR, Holzmann S, Poch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol 1992; 20 Suppl. 3.: 1–7

    Article  Google Scholar 

  29. Sato T, Sasaki N, O’Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35: 514–8

    Article  PubMed  CAS  Google Scholar 

  30. Suryapranta H, Macleod D. Nicorandil and cardiovascular performance in patients with coronary artery disease. J Cardiovasc Pharmacol 1992; 20: S45–S51

    Article  Google Scholar 

  31. Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992; 20: S93–S102

    PubMed  Google Scholar 

  32. Frydman A. A pharmacological profile of nicorandil in humans: an overview. J Cardiovas Pharmacol 1992; 20: S34–S44

    Article  CAS  Google Scholar 

  33. Frampton J, Buckley MM, Fitton A. Nicorandil, a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44: 625–55

    Article  PubMed  CAS  Google Scholar 

  34. Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and anti-ischemic efficacy of nicorandil compared to nifedipine in patients with angina pectoris and coronary heart disease: a double-blind randomised multicenter study. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S67–S73

    Article  PubMed  Google Scholar 

  35. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993; 14 Suppl. B: 30–4

    Article  PubMed  Google Scholar 

  36. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter double-blind randomised studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S74–S81

    Article  PubMed  Google Scholar 

  37. Di Somma S, Liquori V, Verdecchia P, et al. A double blind comparison of nicorandil and metoprolol in patients with effort stable angina [abstract]. Eur Heart J 1990; 11 Suppl.: 80

    Google Scholar 

  38. Hughes LO, Rose EL, Lahiri A, et al. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990; 66: 679–82

    Article  PubMed  CAS  Google Scholar 

  39. Meeter K, Kelder JC, Tijssen JGP, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort. A long-term double-blind randomized study. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S59–S66

    PubMed  Google Scholar 

  40. The Swan Study Group. Comparison of the antiischemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999; 2: 213–7

    Google Scholar 

  41. Why HJF, Richardson PJ. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo. Eur Heart J 1993; 14 Suppl. B: 25–9

    Article  PubMed  Google Scholar 

  42. The IONA Study Group. Trial to show the impact of nicorandil in angina (IONA): design, methodologyt and management [abstract]. Heart 2001; 85: 614

    Google Scholar 

  43. Ciampricotti R, Schotborgh CE, van Herwaarden RH, et al. A comparison of nicorandil with isosorbide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. Am Heart J May 2000; 139(5): 857

    Google Scholar 

  44. Kishida H, Murao S. Effect of a new coronary vasodilator nicorandil on variant angina pectoris. Clin Pharmacol Ther 1987; 42: 166–74

    Article  PubMed  CAS  Google Scholar 

  45. Lablanche JM, Bauters EP, McFadden EP, et al. Potassium channel activators in vasospastic angina. Eur Heart J 1993; 14 Suppl. B: 22–4

    Article  PubMed  Google Scholar 

  46. Matsuo H, Matsubara T, Segawa T, et al. Evidence of pharmacological preconditioning during PTCA by intravenous pre-treatment of ATP-sensitive K+ channel opener nicorandil (abstract). J Am Coll Cardiol 1998; 31 Suppl. A: 458A

    Article  Google Scholar 

  47. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the KATP channels in unstable angina. Eur Heart J 1999; 20: 51–7

    Article  PubMed  CAS  Google Scholar 

  48. Kato K, Iimuna H, Hirosawa K, et al. Clinical evaluation of intravenous SG-75 in treatment of unstable angina: a multicenter double-blind comparative study with intravenous ISDN. Rinshou Iyaku 1991; 7: 2031–54

    Google Scholar 

  49. Sen S, Neuss H, Berg G, et al. Beneficial effects of nicorandil in acute myocardial infarction: a placebo-controlled, double-blind pilot safety study. Br J Cardiol 1998; 4: 208–20

    Google Scholar 

  50. Montogomery H, Suneray M, Carr C, et al. Sinus arrest and severe peripheral vasodilation following cardiopulmonary bypass in a patient taking nicorandil. Cardiovasc Drugs Ther 1997; 11(1):81

    Article  Google Scholar 

  51. Falase BA, Bajaj BS, Wall TJ, et al. Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass. Ann Thorac Surg 1999; 67(4): 1158–9

    Article  PubMed  CAS  Google Scholar 

  52. Hayashi Y, Sawa Y, Ohtake S, et al. Controlled nicorandil administration for myocardial protection during coronary artery bypass grafting under cardiopulmonary bypass. J Cardiovasc Pharmacol 2001; 38: 21–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was received for the preparation of this manuscript. Henry Purcell and Kim Fox have undertaken clinical trials and spoken at symposia sponsored by Aventis (the manufacturer of nicorandil).

Author information

Authors and Affiliations

  1. Cardiology Department, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, England

    Abuzeid H. Gomma, Henry J. Purcell & Kim M. Fox

Authors
  1. Abuzeid H. Gomma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry J. Purcell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kim M. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abuzeid H. Gomma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomma, A.H., Purcell, H.J. & Fox, K.M. Potassium Channel Openers in Myocardial Ischaemia. Drugs 61, 1705–1710 (2001). https://doi.org/10.2165/00003495-200161120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161120-00002

Keywords

Search

Navigation